Related references
Note: Only part of the references are listed.Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance
Stella Apostolaki et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer
Nikolaos Xenidis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
Galatea Kallergi et al.
BREAST CANCER RESEARCH (2009)
Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor
Mark Barok et al.
CANCER LETTERS (2008)
HER2 status and benefit from adjuvant trastuzumab in breast cancer
Soonmyung Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
Galatea Kallergi et al.
BREAST CANCER RESEARCH (2008)
Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer
Michail Ignatiadis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer
N. Xenidis et al.
ANNALS OF ONCOLOGY (2007)
Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance
S. Apostolaki et al.
ANNALS OF ONCOLOGY (2007)
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases:: a possible tool for anti-HER2 therapy management?
A. Vincent-Salomon et al.
BRITISH JOURNAL OF CANCER (2007)
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
Tanja Fehm et al.
BREAST CANCER RESEARCH (2007)
Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients
Nikos Xenidis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients
Erich F. Solomayer et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status
Ye Xu et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients
P Wülfing et al.
CLINICAL CANCER RESEARCH (2006)
Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer
JA Schardt et al.
CANCER CELL (2005)
A pooled analysis of bone marrow micrometastasis in breast cancer
S Braun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Circulating tumor cells in breast cancer:: Correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity
V Müller et al.
CLINICAL CANCER RESEARCH (2005)
Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells
T Fehm et al.
CYTOTHERAPY (2005)
Circulating tumor cells in patients with breast cancer dormancy
SD Meng et al.
CLINICAL CANCER RESEARCH (2004)
Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer
V Bozionellou et al.
CLINICAL CANCER RESEARCH (2004)
HER-2 gene amplification can be acquired as breast cancer progresses
SD Meng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer
N Xenidis et al.
ANNALS OF ONCOLOGY (2003)
Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer
CA Klein et al.
LANCET (2002)
Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance
A Stathopoulou et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors
O Solakoglu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
S Braun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
